Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097812
Status:
COMPLETED
Last Update Posted:
2012-04-27
First Post:
2004-11-30
Brief Title:
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Study to Assess the Safety Tolerability and Efficacy of Switching Patients Currently on Oral Bisphosphonate to Zoledronic Acid
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid compared to those staying on the oral bisphosphonate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None